Effect of spironolactone wash‐out on albuminuria after long‐term treatment in individuals with type 2 diabetes and high risk of kidney disease—An observational follow‐up of the PRIORITY study

Documenti analoghi

• Cardiovascular and non‐renal complications of chronic kidney disease: Managing risk
  di: Peter Rossing, et al.
  Pubblicazione: (2024)
• Slowing the progression of diabetic and non‐diabetic kidney disease: A summary of the current evidence base for sodium‐glucose co‐transporter‐2 inhibitors
  di: Viktor Rotbain Curovic, et al.
  Pubblicazione: (2024)
• Performance of new and panel CKD‐EPI equations in European adults with type 2 diabetes
  di: Esben Iversen, et al.
  Pubblicazione: (2024)
• Effect of Dapagliflozin on Measured vs. Panel‐Estimated Glomerular Filtration Rate
  di: Esben Iversen, et al.
  Pubblicazione: (2024)
• Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non‐diabetic chronic kidney disease
  di: Victor Wasehuus, et al.
  Pubblicazione: (2025)